Controlled release and taste masking oral pharmaceutical composition
DC CAFCFirst Claim
Patent Images
1. An oral dosage form consisting essentially of (1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:
- (a) 9 mg of budesonide;
(b) hydroxypropyl cellulose; and
(c) magnesium stearate, stearic acid, or a mixture thereof;
and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides an AUC0-infinity of said budesonide in said human of about 16431.2±
10519.8 (pg)×
(h)/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
69 Citations
22 Claims
-
1. An oral dosage form consisting essentially of (1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:
-
(a) 9 mg of budesonide; (b) hydroxypropyl cellulose; and (c) magnesium stearate, stearic acid, or a mixture thereof; and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides an AUC0-infinity of said budesonide in said human of about 16431.2±
10519.8 (pg)×
(h)/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. An oral dosage form consisting essentially of (1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:
-
(a) 9 mg of budesonide; (b) hydroxypropyl cellulose; and (c) magnesium stearate, stearic acid, or a mixture thereof; and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides a Cmax of said budesonide in said human of about 1348.8±
958.8 pg/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20)
-
-
21. A method of treating a human subject with ulcerative colitis, comprising administering to said human subject an oral dosage form consisting essentially of
(1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising: -
(a) 9 mg of budesonide; (b) hydroxypropyl cellulose; and (c) magnesium stearate, stearic acid, or a mixture thereof; and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides an AUC0-infinity, of said budesonide in said human of about 16431.2±
10519.8 (pg)×
(h)/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.
-
-
22. A method of treating a human subject with ulcerative colitis, comprising administering to said human subject an oral dosage form consisting essentially of (1) a tableted core, and (2) a gastro-resistant film on said tableted core, wherein said tableted core consists of a matrix comprising:
-
(a) 9 mg of budesonide; (b) hydroxypropyl cellulose; and (c) magnesium stearate, stearic acid, or a mixture thereof; and wherein following oral administration of the oral dosage form to a human, the oral dosage form provides a Cmax of said budesonide in said human of about 1348.8±
958.8 pg/mL, wherein said oral dosage form is in the form of a tablet and provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.
-
Specification